Altre lingue Purple Biotech Ltd Nasdaq

Azioni

PPBT

US74638P1093

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:00 20/05/2024			Variaz. 5gg	Var. 1 gen.
0,5632 ^USD	+1,65%		+8,31%	-27,79%

25/04	Lo studio randomizzato di Fase 2 CM24 sul tumore del pancreas di Purple Biotech Ltd. è stato selezionato come poster di presentazione dell'abstract più recente all'incontro annuale ASCO 2024.	CI
14/03	Purple Biotech riporta una prova preclinica di concetto per la sua tecnologia di piattaforma Tribody	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Purple Biotech Ltd.'s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting	25/04
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024	28/03
Purple Biotech Reports Preclinical Proof of Concept for Its Tribody Platform Technology	14/03
Purple Biotech : Immediate Report	06/03
6K:Fourth Quarter and Full-Year 2023 Financial Results	05/03
Purple Biotech Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results	05/03
Purple Biotech Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	05/03
Purple Biotech Presents Data of Its Phase 1 Head & Neck Cancer of NT219 in Combination with Cetuximab At ESMO TAT Congress 2024	27/02
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024	27/02
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial	13/02
Purple Biotech Reaches Recommended Phase 2 Dose for NT219	01/02
Purple Biotech Ltd. Announces Executive Changes	20/12
Purple Biotech Ltd. Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial	14/12
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial	14/12
Papillary Thyroid Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	30/11
Purple Biotech Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	21/11
Purple Biotech Reports Third Quarter 2023 Financial Results	21/11
Purple Biotech Fortifies NT219 Patent Protection	02/11
Purple Biotech : Other Report or Announcement	31/10/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Purple Biotech Ltd Nasdaq

Azioni

PPBT

US74638P1093

Altre lingue

Filtri